In this edition:
Sub-lobar resection for T1aN0 NSCLC
NADIM II study: Survival outcomes
IMpower010: Survival outcomes
Personalised smoking cessation support
Sotorasib for KRAS-mutated NSCLC
Tepotinib for METex14 skipping NSCLC
Pooled analysis of 2nd-line pembrolizumab
Multi-drug biomarker-directed treatments
Nivolumab plus temozolomide
Talazoparib plus temozolomide
Please login below to download this issue (PDF)